List of Nocdurna drug patents

Nocdurna is owned by Ferring Pharms Inc.

Nocdurna contains Desmopressin Acetate.

Nocdurna has a total of 10 drug patents out of which 0 drug patents have expired.

Nocdurna was authorised for market use on 21 June, 2018.

Nocdurna is available in tablet;sublingual dosage forms.

Nocdurna can be used as treatment of nocturia due to nocturnal polyuria in adults; treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration, treatment of nocturia due to nocturnal polyuria in adults, treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration.

The generics of Nocdurna are possible to be released after 13 April, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220747 FERRING PHARMS INC Methods using desmopressin acetate in orodispersible form
May, 2023

(3 months from now)

US9504647 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(3 months from now)

US9919025 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(3 months from now)

US10307459 FERRING PHARMS INC Pharmaceutical formulations of desmopressin
May, 2023

(3 months from now)

US7947654 FERRING PHARMS INC Pharmaceutical formulations
Dec, 2023

(10 months from now)

US8802624 FERRING PHARMS INC Methods of treatment using orodispersible desmopressin pharmaceutical formulations
Dec, 2023

(10 months from now)

US7560429 FERRING PHARMS INC Orodispersible dosage forms of desmopressin acetate
Feb, 2024

(11 months from now)

US11020448 FERRING PHARMS INC Methods comprising desmopressin
May, 2029

(6 years from now)

US10137167 FERRING PHARMS INC Methods comprising desmopressin
May, 2029

(6 years from now)

US9974826 FERRING PHARMS INC Methods comprising desmopressin
Apr, 2030

(7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in